BTBD7 Blocking Peptide Summary
Synthetic peptide corresponding to unique epitope on Btbd7 protein between aa 1095-1138. The peptide sequence selected was post synthetically modified to achieve desired antigenicity before covalently coupling to a carrier protein.
NCBI Accession #: NP_001002860
NCBI Accession #: NP_001002860
Source: Synthetic
Synthetic
Blocking Peptide
BTBD7
>85%, by HPLC
Applications/Dilutions
This peptide is useful as a blocking peptide for NBP1-49652. For further blocking peptide related protocol, click here. Applications: Immmunodepletion, Competition Assay
126 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Packaging, Storage & Formulations
Store at -20C. Avoid freeze-thaw cycles.
Sodium Bicarbonate buffer, pH 8.00 containing up to 10% DMSO
2.5 mg/ml
>85%, by HPLC
Alternate Names for BTBD7 Blocking Peptide
- BTB (POZ) domain containing 7
- DKFZp686N0544
- FLJ10648
- FUP1BTB/POZ domain-containing protein 7
- KIAA1525
- MGC48310
Background
Cancer cells especially human hepatocellular carcinoma (HCC) differentially express many genes as determined by cDNA microarrays. One of these genes is Btbd7 whose function was not known. When transfected in NIH3T3 cells this gene exhibited enhanced cell proliferation activity by MTT assay. The enhanced tumorigencity was blocked by anti-sense RNA experiments (1). Recently it has been shown that Btbd7 regulate epithelial cell dynamics and branching morphogenesis. The organ development during embryogenesis requires extensive branching of epithelia via formation of cleft and buds. These branches are developed by local outgrowth or by formation of cleft that further divide epithelia in to buds. The bud or tubule extension is controlled and regulated by various growth factors. These branching finally led to formation of various organs. Cellular matrix protein fibronectin is required for salivary, lung and kidney branching (3). The edges of fibronectin translocates inwards as cleft accompanied by loss of E-cadherin in cells adjacent to fibronectin. The Btbd7 activity was noticed at cell cleft forming sites (2). The cleft formation involves buds delineation of buds by conversion of epithelial cell-cell adhesion to cell-matrix adhesion. Btbd7 provides a mechanistic link between the extracellular matrix and cleft propagation via its highly discrete expression that control epithelial cell motility by interaction with other cellular architectural and scaffolding proteins like Snail2 (slug), E-cadherin (4). The Btbd7 antibodies were generated using peptide corresponding to C-terminal domain of the human Btbd7 gene. The Btbd7 antibodies are affinity purified over immobilized antigen based affinity chromatography, and the purified immunoglobulins are stabilized in antibody stabilization buffer. Antibodies to Btbd7 (Btbd-701AP) will label ~144kDa protein in Western blot positive control for Btbd7 (PC-Btbd7).
Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Peptides and proteins are guaranteed for 3 months from date of receipt.